市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 混合的 |
| Biotechnology (全球的) | 看跌 | 混合的 | |
| 股票 | Cabaletta Bio, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.00 |
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.10% |
| 机构持股比例 | 79.61% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2024 | 2,760,888 |
| Superstring Capital Management Lp | 31 Dec 2024 | 822,293 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 25.00 (HC Wainwright & Co., 1,916.13%) | 购买 |
| 中 | 22.00 (1,674.19%) | |
| 低 | 3.00 (Wells Fargo, 141.94%) | 保留 |
| 平均值 | 16.00 (1,190.32%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 1.17 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 01 Apr 2025 | 23.00 (1,754.84%) | 购买 | 1.17 |
| HC Wainwright & Co. | 01 Apr 2025 | 25.00 (1,916.13%) | 购买 | 1.17 |
| 18 Feb 2025 | 25.00 (1,916.13%) | 购买 | 2.33 | |
| Morgan Stanley | 01 Apr 2025 | 22.00 (1,674.19%) | 购买 | 1.17 |
| UBS | 01 Apr 2025 | 7.00 (464.52%) | 购买 | 1.17 |
| Wells Fargo | 01 Apr 2025 | 3.00 (141.94%) | 保留 | 1.17 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合